Patents by Inventor N. Charle Morcos

N. Charle Morcos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5865738
    Abstract: A method and apparatus for evaluating the viability of a tissue of interest, particularly that presents as dead but may be merely stunned or hibernating with reduced or no obvious activity, such as contractility. Dynamic measurement of oxidative metabolism or other metaboic function permits distinguishing between different stages of compromised tissue such as myocardium. Measurements can be made using near-infrared illumination and detection coupled with infusion of one or more metabolic substrates to the region of interest to evaluate whether a metabolic pathway cascade or a trans-membrane ionic potential are intact and thereby provide an indication of the viability of the cell. One preferred instrument includes a catheter having a tip configured to be positioned adjacent to the tissue to be monitored. Optical fibers extend through the catheter to transmit a monitoring light beam from the tip into the tissue, and to receive a cytochrome-redox-response-dependent light beam from the tissue.
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: February 2, 1999
    Assignee: Regents of the University of California
    Inventors: N. Charle Morcos, Roger A. Nahas
  • Patent number: 5497770
    Abstract: A method and apparatus for evaluating the viability of a tissue of interest, particularly that presents as dead but may be merely stunned or hibernating with reduced or no contractility. Dynamic measurement of oxidative metabolism permits distinguishing between different stages of compromised myocardium. Measurements can be made using near-infrared illumination and detection coupled with infusion of one or more metabolic substrates to the region of interest to evaluate whether a metabolic pathway cascade or a trans-membrane ionic potential are intact and thereby provide an indication of the viability of the cell.
    Type: Grant
    Filed: January 14, 1994
    Date of Patent: March 12, 1996
    Assignee: The Regents of the University of California
    Inventors: N. Charle Morcos, Roger A. Nahas
  • Patent number: 5163898
    Abstract: A photochemical method is described for treating cancer wherein phycocyanin is administered to a patient suffering from internal or skin cancer. Once administered, phycocyanin is selectively taken up into cancer cells, and upon subsequent irradiation destruction of the cancer cells occurs. Phycocyanin offers several advantages over prior art chemicals used for similar purposes. First, it is only marginally sensitive to the ultraviolet portion of the spectrum; consequently patients can be irradiated without concern that they will be sensitized to subsequent exposure to sunlight. Second, phycocyanin is selectively taken up into cancer cells with little or no uptake by surrounding normal cells. This ensures that upon subsequent irradiation that the tumors are selectively destroyed with little or no damage to the surrounding cells or tissue. A variety of different types of cancer cells can be effectively treated by this method; treatments of breast cancer, leukemia and murine tumors are described.
    Type: Grant
    Filed: December 28, 1990
    Date of Patent: November 17, 1992
    Assignee: The Regents of the University of California
    Inventors: N. Charle Morcos, Walter L. Henry
  • Patent number: 4886831
    Abstract: A photochemical method is described for treating atherosclerosis or cancer wherein phycocyanin is injected into a patient suffering from one of these diseases. Once injected, phycocyanin is selectively taken up into atherosclerotic plaques or cancer cells, and upon subsequent irradiation destruction of the atherosclerotic plaques or cancer cells occurs. Phycocyanin offers several advantages over prior art chemicals used for similar purposes. First it is only marginally sensitive to the ultraviolet portion of the spectrum; consequently patients can be irradiated without concern that they will be sensitized to subsequent exposure to sunlight. Second, phycocyanin is selectively taken up into atherosclerotic plaques, with little or no uptake by surrounding normal cells. This ensures that upon subsequent irradiation that the atherosclerotic plaques are selectively destroyed with little or no damage to the surrounding cells or tissue.
    Type: Grant
    Filed: March 16, 1987
    Date of Patent: December 12, 1989
    Assignee: The Regents of the University of California
    Inventors: N. Charle Morcos, Walter L. Henry